Sublocade (Buprenorphine) Patent Expiration, LOE Window & CMS Spending
Sublocade (Buprenorphine) by Indivior: FDA Orange Book LOE 2038-06-22, 12 AB generics, $599.4M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Indivior |
| FDA Application & Pathway | N209819 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2038-06-22 |
| Orange Book Patents (*PED Extensions) | 13 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 12 |
| 2024 CMS Total Public Spend | $599.4M |
| 2024 Medicare Part D Spend | $50.5M |
| 2024 Medicaid Spend | $548.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |